/VRAY

VRAY Stock - ViewRay, Inc.

Q: What is the analyst price target for VRAY?

Analyst price target information is not currently available for VRAY.

Q: What is VRAY's market cap?

Market capitalization information is not currently available for VRAY.

Healthcare|Medical - Devices|NASDAQ

$0.03+0.00%

+$0.00 (+0.00%) • Jan 16

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+25500.0%upside

Target: $6.40

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for VRAY

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2018

FY2019

FY2020

FY2021

FY2022

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.70

52W High$0.04

52W Low$0.02

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020	FY2019	FY2018
Revenue	$102.21M	$70.12M	$57.02M	$87.78M	$80.96M
Gross Profit	$10.04M	$335,000	$-4,059,000	$-5,478,000	$6.60M
Gross Margin	9.8%	0.5%	-7.1%	-6.2%	8.2%
Operating Income	$-107,127,000	$-103,649,000	$-105,977,000	$-120,795,000	$-75,092,000
Net Income	$-107,533,000	$-106,134,000	$-105,381,000	$-123,073,000	$-76,396,000
Net Margin	-105.2%	-151.4%	-184.8%	-140.2%	-94.4%
EPS	$-0.60	$-0.65	$-0.71	$-1.21	$-0.94

Company Overview

ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, France, Taiwan, the United Kingdom, and internationally. The company provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

Hold / Neutral

100%

Sell / Underperform

Analyst Consensus🔴 Bearish

0 Bullish4 Neutral/Bearish

Price Targets

Average Target

↑ 5233.3% Upside

Now

Low

Average

High

Based on 3 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
May 11th 2023	B. Riley Securities	Downgrade	Neutral	$1← $4
April 17th 2023	Jefferies	Downgrade	Hold	$1.25← $7
April 14th 2023	Oppenheimer	Downgrade	Perform	-
April 14th 2023	BTIG Research	Downgrade	Neutral	-
April 14th 2023	Stifel	Downgrade	Hold	$1.75← $7

Earnings History & Surprises

VRAY

Beat Rate

24%

Last 17 quarters

Avg Surprise

-5.4%

EPS vs Estimate

Beats / Misses

4/10

3 met exactly

Latest EPS

$-0.15

Q3 2023

EPS Surprise History

Q4 21

+6.3%

$-0.15vs$-0.16

Q1 22

-6.7%

$-0.16vs$-0.15

Q2 22

+12.5%

$-0.14vs$-0.16

Q3 22

0.0%

$-0.15vs$-0.15

Q4 22

0.0%

$-0.14vs$-0.14

Q1 23

+6.3%

$-0.15vs$-0.16

Q2 23

-6.7%

$-0.16vs$-0.15

Q3 23

-7.1%

$-0.15vs$-0.14

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2024	May 8, 2024	—	—	—	—
Q1 2024	Feb 26, 2024	—	—	—	—
Q4 2023	Oct 30, 2023	$-0.14	—	—	—
Q3 2023	Aug 1, 2023	$-0.14	$-0.15	-7.1%	✗ MISS
Q2 2023	May 10, 2023	$-0.15	$-0.16	-6.7%	✗ MISS
Q1 2023	Feb 27, 2023	$-0.16	$-0.15	+6.3%	✓ BEAT
Q4 2022	Nov 1, 2022	$-0.14	$-0.14	0.0%	= MET
Q3 2022	Aug 2, 2022	$-0.15	$-0.15	0.0%	= MET
Q2 2022	May 5, 2022	$-0.16	$-0.14	+12.5%	✓ BEAT
Q1 2022	Feb 24, 2022	$-0.15	$-0.16	-6.7%	✗ MISS
Q4 2021	Nov 4, 2021	$-0.16	$-0.15	+6.3%	✓ BEAT
Q3 2021	Aug 5, 2021	$-0.16	$-0.19	-18.8%	✗ MISS
Q2 2021	May 6, 2021	$-0.16	$-0.17	-6.3%	✗ MISS
Q1 2021	Mar 4, 2021	$-0.17	$-0.18	-5.9%	✗ MISS
Q4 2020	Nov 5, 2020	$-0.17	$-0.19	-11.8%	✗ MISS
Q3 2020	Jul 30, 2020	$-0.16	$-0.18	-12.5%	✗ MISS
Q2 2020	Apr 30, 2020	$-0.19	$-0.19	0.0%	= MET
Q1 2020	Mar 12, 2020	$-0.25	$-0.31	-24.0%	✗ MISS
Q4 2019	Nov 12, 2019	$-0.27	$-0.21	+22.2%	✓ BEAT
Q3 2019	Aug 8, 2019	$-0.23	$-0.32	-39.1%	✗ MISS